Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2008 1
2009 1
2010 2
2012 3
2013 5
2014 12
2015 9
2016 7
2017 6
2018 3
2019 3
2020 3
2021 3
2022 4
2023 7
2024 4

Text availability

Article attribute

Article type

Publication date

Search Results

64 results

Results by year

Filters applied: . Clear all
Page 1
PARP Inhibitors for Breast Cancer Treatment: A Review.
Morganti S, Marra A, De Angelis C, Toss A, Licata L, Giugliano F, Taurelli Salimbeni B, Berton Giachetti PPM, Esposito A, Giordano A, Bianchini G, Garber JE, Curigliano G, Lynce F, Criscitiello C. Morganti S, et al. Among authors: esposito a. JAMA Oncol. 2024 Mar 21. doi: 10.1001/jamaoncol.2023.7322. Online ahead of print. JAMA Oncol. 2024. PMID: 38512229
NOTCH1-mutated chronic lymphocytic leukemia displays high endoplasmic reticulum stress response with druggable potential.
Silva Barcelos EC, Rompietti C, Adamo FM, Dorillo E, De Falco F, Del Papa B, Baldoni S, Nogarotto M, Esposito A, Capoccia S, Geraci C, Sorcini D, Stella A, Arcaleni R, Tini V, Imbroisi Valle Errera F, Rosati E, Sportoletti P. Silva Barcelos EC, et al. Among authors: esposito a. Front Oncol. 2023 Sep 25;13:1218989. doi: 10.3389/fonc.2023.1218989. eCollection 2023. Front Oncol. 2023. PMID: 37817771 Free PMC article.
The CDK4/6 inhibitors biomarker landscape: The most relevant biomarkers of response or resistance for further research and potential clinical utility.
Antonarelli G, Taurelli Salimbeni B, Marra A, Esposito A, Locatelli MA, Trapani D, Pescia C, Fusco N, Curigliano G, Criscitiello C. Antonarelli G, et al. Among authors: esposito a. Crit Rev Oncol Hematol. 2023 Dec;192:104148. doi: 10.1016/j.critrevonc.2023.104148. Epub 2023 Oct 1. Crit Rev Oncol Hematol. 2023. PMID: 37783318 Review.
Immune-Related Adverse Event Likelihood Score Identifies "Pure" IRAEs Strongly Associated With Outcome in a Phase I-II Trial Population.
Mazzarella L, Giugliano F, Nicolo E, Esposito A, Crimini E, Tini G, Uliano J, Corti C, D'Amico P, Aliaga PT, Valenza C, Repetto M, Antonarelli G, Ascione L, Vivanet G, Berton Giachetti P, Minchella I, Belli C, Locatelli M, Criscitiello C, Curigliano G. Mazzarella L, et al. Among authors: esposito a. Oncologist. 2024 Feb 2;29(2):e266-e274. doi: 10.1093/oncolo/oyad239. Oncologist. 2024. PMID: 37715957 Free PMC article.
Baseline Tumor Size as Prognostic Index in Patients With Advanced Solid Tumors Receiving Experimental Targeted Agents.
Nicolò E, Tarantino P, D'Ecclesiis O, Antonarelli G, Boscolo Bielo L, Marra A, Gandini S, Crimini E, Giugliano F, Zagami P, Corti C, Trapani D, Morganti S, Criscitiello C, Locatelli M, Belli C, Esposito A, Minchella I, Cristofanilli M, Tolaney SM, Curigliano G. Nicolò E, et al. Among authors: esposito a. Oncologist. 2024 Jan 5;29(1):75-83. doi: 10.1093/oncolo/oyad212. Oncologist. 2024. PMID: 37548439 Free PMC article. Review.
Therapeutic Targeting Potential of Novel Silver Nanoparticles Coated with Anti-CD20 Antibody against Chronic Lymphocytic Leukemia.
Adamo FM, Silva Barcelos EC, De Falco F, Dorillo E, Rompietti C, Sorcini D, Stella A, Del Papa B, Baldoni S, Esposito A, Geraci C, Arcaleni R, Pennetta C, Ragonese F, Moretti L, Mameli M, Di Ianni M, Rosati E, Fioretti B, Sportoletti P. Adamo FM, et al. Among authors: esposito a. Cancers (Basel). 2023 Jul 14;15(14):3618. doi: 10.3390/cancers15143618. Cancers (Basel). 2023. PMID: 37509279 Free PMC article.
Impact of soluble tumor necrosis factor-related apoptosis-inducing ligand released by engineered adipose mesenchymal stromal cells on white blood cells.
Casari G, Dall'Ora M, Melandri A, Masciale V, Chiavelli C, Prapa M, Neri G, Spano MC, Murgia A, D'Esposito A, Baschieri MC, Ceccherelli GB, Dominici M, Grisendi G. Casari G, et al. Among authors: d esposito a. Cytotherapy. 2023 Jun;25(6):605-614. doi: 10.1016/j.jcyt.2023.02.008. Epub 2023 Apr 1. Cytotherapy. 2023. PMID: 37012089 Free article.
Molecular tumour board at European Institute of Oncology: Report of the first three year activity of an Italian precision oncology experience.
Repetto M, Crimini E, Boscolo Bielo L, Guerini-Rocco E, Ascione L, Bonfanti A, Zanzottera C, Mazzarella L, Ranghiero A, Belli C, Criscitiello C, Esposito A, Barberis MCP, Curigliano G. Repetto M, et al. Among authors: esposito a. Eur J Cancer. 2023 Apr;183:79-89. doi: 10.1016/j.ejca.2023.01.019. Epub 2023 Jan 31. Eur J Cancer. 2023. PMID: 36801623
64 results